Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer/GSK vardenafil 

Executive Summary

Trade name for erectile dysfunction disorder drug vardenafil is Levitra, Bayer and GlaxoSmithKline announce. Bayer had earlier referred to the drug as Nuviva; the name was one of several submitted to FDA for approval (1"The Pink Sheet" March 18, p. 29). The companies received an "approvable" letter for vardenafil in July; approval is expected in 2003 (2"The Pink Sheet" July 29, In Brief)...

You may also be interested in...

Analysts Presentations, Conference Calls In Brief

Bayer's vardenafil is Nuviva: Bayer's brand name for vardenafil is Nuviva, R&D Board Committee Chair Frank Morich, PhD, announced during a press briefing March 13. An NDA for the erectile dysfunction drug is pending at FDA; Bayer expects approval in the second half of 2002. Nuviva will be co-promoted with GlaxoSmithKline...

Prescience Point Capital Launches Proxy Fight To Change MiMedx's Board

Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.

In Flood Of 2020 Sanitizer Launches, Unilever’s Suave Brand Tops US Category Sales

Unilever’s Suave brand led new sanitizer product sales in 2020, when hand sanitizers total sales grew 569%, according to IRI. Sales of rinseable hand-soap sales grew 64% and antiseptics 19%.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts